Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Director Shareholding

24 Feb 2005 07:04

Marchpole Holdings PLC24 February 2005 24 February 2005 Marchpole Holdings plc (the 'Company') Directors' interests Following approval by the Remuneration Committee, the executive Directors of theCompany have been granted the following share options ('Options') over newordinary shares of 1 pence each ('Ordinary Shares') under the Marchpole Holdingsplc 2002 Unapproved Share Option Scheme adopted by the Company at the AnnualGeneral Meeting held on 31 October 2002. All Options were granted on 21 February 2005, are exercisable at a price of25.75 pence per share and vest and become exercisable in three equal tranches onand from each twelfth month anniversary of the date of grant on the attainmentof a market capitalisation of the Company of £60 million, £70 million and £80million respectively. Director Number of Options over new Ordinary SharesGreg Tufnell, Chief Executive 900,000Justin Hampshire, Finance Director 900,000Michael Morris, Executive Director 900,000 The additional grant of 3,250,000 Options in the Company has been made toMichael Morris at a exercise price of 25.75 pence per share, such share optionsvesting and becoming exercisable in two equal tranches on each twelfth monthanniversary on the date of grant and on the achievement of a marketcapitalisation of the Company of £50 million and £55 million respectively. The Directors have the following interests in the Company: Director Number of Ordinary % of issued Shares share capital Christopher Phillips, Chairman 500,000 0.38Greg Tufnell, Chief Executive - -Justin Hampshire, Finance Director 500,000 0.38Michael Morris, Executive Director 25,521,715 19.21Raymond Harris, Non-Executive Director 30,000 0.02 The Michael Morris 1997 Trust 10,000,000 7.55 Enquiries: Justin Hampshire, Marchpole Holdings 020 7908 7777 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Sep 20191:00 pmRNSNotice of Results
6th Sep 20197:00 amRNSBlock listing Interim Review
4th Sep 20191:00 pmRNSMereo announces phase 2b data at ASBMR Meeting
16th Aug 20191:51 pmRNSDirector/PDMR Shareholding
15th Aug 20194:59 pmRNSPDMR Shareholding
12th Aug 20194:41 pmRNSSecond Price Monitoring Extn
12th Aug 20194:35 pmRNSPrice Monitoring Extension
9th Aug 20194:35 pmRNSPrice Monitoring Extension
31st Jul 201912:51 pmRNSDirector Declaration
25th Jul 20194:56 pmRNSPDMR Shareholding
24th Jul 201910:08 amRNSDirector/PDMR Shareholding
19th Jul 20191:21 pmRNSDirector/PDMR Shareholding
16th Jul 20191:00 pmRNSAppointment of Richard Francis
15th Jul 20191:00 pmRNSSuccessful Type B Meeting with U.S. FDA
8th Jul 20193:54 pmRNSHolding(s) in Company
3rd Jul 20194:41 pmRNSSecond Price Monitoring Extn
3rd Jul 20194:35 pmRNSPrice Monitoring Extension
27th Jun 20193:33 pmRNSHolding(s) in Company
26th Jun 20194:36 pmRNSHolding(s) in Company
21st Jun 20191:00 pmRNSConversion of loan note and issue of equity
20th Jun 20197:00 amRNSResult of AGM
13th Jun 20191:00 pmRNSUpdate on Etigilimab (TIGIT) Partnership
30th May 20197:00 amRNSPositive early 6 month data
23rd May 20194:11 pmRNSDirector/PDMR Shareholding
22nd May 20199:45 amRNSPDMR Shareholding
21st May 20193:08 pmRNSDirector/PDMR Shareholding
20th May 20197:00 amRNSNotice of AGM
8th May 20191:53 pmRNSDirector/PDMR Shareholding
7th May 20197:00 amRNSIssue of Warrants
7th May 20197:00 amRNSRe-release: Intention to Purchase Shares
3rd May 20195:00 pmRNSIntention to Purchase Shares by Trustee of EBT
3rd May 20192:02 pmRNSDirector/PDMR Shareholding
1st May 20193:47 pmRNSDirector/PDMR Shareholding
30th Apr 20193:15 pmRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSPublication of Annual Report and Accounts
29th Apr 20197:00 amRNSPrelims Results for year ended December 31 2018
26th Apr 20193:01 pmRNSDirector/PDMR Shareholding
25th Apr 20193:36 pmRNSHolding(s) in Company
25th Apr 20193:29 pmRNSHolding(s) in Company
24th Apr 20192:30 pmRNSAdmission to Trading
23rd Apr 20192:25 pmRNSCompletion of Merger
18th Apr 20197:00 amRNSMerger Update
15th Apr 20197:00 amRNSSuccessful end of Phase 2 Meeting with FDA
21st Mar 20197:00 amRNSPublication of Form F-4
15th Mar 201911:45 amRNSUpdate on Proposed Combination of Mereo & OncoMed
13th Mar 201911:00 amRNSMereo CEO appointed NED of Elanco Animal Health
6th Mar 20197:00 amRNSBlock Listing Interim Review
5th Mar 20191:32 pmRNSMereo to present at Cowen and Company Conference
22nd Feb 20191:50 pmRNSUpdate on Proposed Transaction with OncoMed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.